| Literature DB >> 36199305 |
Yan Zhang1, Zhiwu Long1, Longjia Yan1,2, Li Liu1,2, Lan Yang1,2, Yi Le1,2.
Abstract
Polysubstituted phenylisoxazoles were designed and synthesized to discover new antibacterial agents via [3 + 2] cycloaddition. Thirty-five compounds with a phenylisoxazole scaffold were characterized by NMR, HRMS, and X-ray techniques. After being evaluated against Xanthomonas oryzae (Xoo), Pseudomonas syringae (Psa), and Xanthomonas axonopodis (Xac), 4-nitro-3-phenylisoxazole derivatives were found to better antibacterial activities. Further studies have shown that the EC50 values of these compounds were much better than that of the positive control, bismerthiazol. This journal is © The Royal Society of Chemistry.Entities:
Year: 2022 PMID: 36199305 PMCID: PMC9455768 DOI: 10.1039/d2ra05009a
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Important antibacterial agents in market.
Reaction optimization of (E)-benzaldehyde oxime and phenylacetylenea,b
|
| |||||
|---|---|---|---|---|---|
| Entry | Additive | Base | Solvent |
| Yield (%) |
| 1 | NCS | DBU | DMF | 25 | 65 (63) |
| 2 | NCS | DBU | CH2Cl2 | 25 | 38 |
| 3 | NCS | DBU | THF | 25 | 31 |
| 4 | NCS | DBU | Dioxane | 25 | None |
| 5 | NBS | DBU | DMF | 25 | 17 |
| 6 | NIS | DBU | DMF | 25 | 19 |
| 7 | PIFA | DBU | DMF | 25 | 39 |
| 8 | Chloramine | DBU | DMF | 25 | 37 |
| 9 | NCS | Cs2CO3 | DMF | 25 | 43 |
| 10 | NCS | K2CO3 | DMF | 25 | 51 |
| 11 | NCS | NaO | DMF | 25 | 51 |
| 12 | NCS | Na2CO3 | DMF | 25 | 53 |
| 13 | NCS | Pyrrolidine | DMF | 25 | 47 |
| 14 | NCS | NaOH | DMF | 25 | 52 |
| 15 | NCS | DMAP | DMF | 25 | 55 |
| 16 | NCS | DIEA | DMF | 25 | 80 |
| 17 | NCS | DABCO | DMF | 25 | 63 |
| 18 | NCS | TEA | DMF | 25 | 85 |
| 19 | NCS | TEA | DMF | 50 | 84 |
| 20 | NCS | TEA | DMF | 75 | 79 |
| 21 | NCS | TEA | DMF | 100 | 74 |
Reagents and conditions: 1a (1 mmol), 2a (1.2 mmol), additive (2 mmol), base (1 mmol), solvent (6 mL), 6 h.
Isolated yields.
Reagents and conditions: 1a (1 mmol), 2a (1.2 mmol), NCS (1.2 mmol), DBU (1 mmol), DMF (6 mL), 6 h.
Reaction examples of 1 and 2a
|
|
|---|
|
|
Reagents and conditions: 1 (1 mmol), 2 (1.2 mmol), NCS (2 mmol), TEA (1 mmol), DMF (6 mL), 25 °C, 6 h.
Reaction examples of 1 and 4a
|
|
|---|
|
|
Reagents and conditions: 1 (1 mmol), 4 (1.2 mmol), NCS (2 mmol), TEA (1 mmol), DMF (6 mL), 25 °C, 6 h.
Fig. 2X-ray structures of 5p, 5q, and 5r.
Scheme 1Proposed mechanism.
Scheme 2Complementary experiments.
Antibacterial activities of compounds 3 and 5 against Xoo, Xac and Psaa
| Entry | Cpd |
|
|
| |||
|---|---|---|---|---|---|---|---|
| 100 | 50 | 100 | 50 | 100 | 50 | ||
| 1 | 3a | — | — | — | — | 9.6 ± 2.1 | — |
| 2 | 3b | — | — | — | — | 10.7 ± 3.8 | — |
| 3 | 3c | — | — | 38.2 ± 3.7 | 15.0 ± 2.4 | 15.8 ± 1.4 | — |
| 4 | 3d | — | — | 35.5 ± 2.8 | 12.9 ± 1.7 | 12.6 ± 1.1 | — |
| 5 | 3e | — | — | 36.1 ± 3.2 | 14.6 ± 2.5 | 14.9 ± 0.8 | — |
| 6 | 3f | — | — | — | — | 14.5 ± 4.5 | — |
| 7 | 3g | — | — | 43.5 ± 5.9 | 38.1 ± 2.1 | 19.6 ± 1.5 | — |
| 8 | 3h | — | — | 35.1 ± 3.7 | 20.3 ± 5.0 | 18.6 ± 5.8 | — |
| 9 | 3i | — | — | 44.8 ± 3.6 | 21.6 ± 2.5 | 19.3 ± 4.5 | 18.3 ± 7.4 |
| 10 | 3j | — | — | 14.4 ± 2.7 | — | 16.8 ± 4.9 | 9.3 ± 4.1 |
| 11 | 3k | — | — | 46.7 ± 3.6 | 36.1 ± 4.1 | 19.2 ± 4.2 | — |
| 12 | 3l | — | — | 72.8 ± 2.5 | 35.1 ± 1.3 | 16.0 ± 0.9 | 5.8 ± 2.2 |
| 13 | 5a | 29.6 ± 0.9 | 22.4 ± 3.6 | 34.4 ± 3.5 | 25.3 ± 2.6 | 27.4 ± 0.4 | 17.7 ± 0.2 |
| 14 | 5b | 41.1 ± 5.7 | 28.7 ± 3.1 | 45.8 ± 1.7 | 29.5 ± 4.3 | 27.0 ± 5.7 | 14.9 ± 2.8 |
| 15 | 5c | 32.9 ± 4.1 | 31.5 ± 2.2 | 39.0 ± 8.2 | 12.3 ± 6.0 | 27.6 ± 4.9 | 16.5 ± 2.0 |
| 16 | 5d | 42.4 ± 5.2 | 27.6 ± 3.4 | 46.7 ± 1.8 | 28.6 ± 4.1 | 26.8 ± 5.3 | 13.7 ± 2.5 |
| 17 | 5e | 42.2 ± 1.7 | 10.4 ± 5.9 | 64.0 ± 4.6 | 56.8 ± 5.1 | 29.6 ± 2.2 | 16.0 ± 3.0 |
| 18 | 5f | 33.5 ± 1.1 | 24.1 ± 1.6 | 60.6 ± 7.4 | 46.2 ± 4.2 | 26.8 ± 2.7 | 14.3 ± 2.6 |
| 19 | 5g | 37.9 ± 6.9 | 26.8 ± 8.3 | 51.9 ± 8.4 | 29.3 ± 6.6 | 25.3 ± 1.9 | 12.0 ± 1.4 |
| 20 | 5h | 48.4 ± 2.8 | 19.3 ± 4.7 | 51.3 ± 2.5 | 26.0 ± 6.5 | 25.7 ± 1.5 | 13.4 ± 1.6 |
| 21 | 5i | 34.9 ± 1.6 | 26.5 ± 5.1 | 70.4 ± 5.0 | 51.6 ± 3.4 | 26.0 ± 0.7 | 14.8 ± 5.1 |
| 22 | 5j | 37.7 ± 1.4 | 28.9 ± 4.3 | 63.7 ± 4.5 | 46.2 ± 2.8 | 28.2 ± 0.5 | 16.4 ± 5.8 |
| 23 | 5k | 36.8 ± 1.9 | 28.7 ± 6.7 | 72.9 ± 6.1 | 53.7 ± 4.9 | 27.1 ± 0.8 | 15.3 ± 6.6 |
| 24 | 5l | 42.2 ± 1.7 | 10.4 ± 5.9 | 74.0 ± 4.6 | 56.8 ± 7.1 | 26.5 ± 0.7 | 16.6 ± 4.5 |
| 25 | 5m | 33.5 ± 1.1 | 24.1 ± 1.6 | 60.6 ± 2.4 | 46.2 ± 5.2 | 27.1 ± 0.8 | 15.3 ± 3.6 |
| 26 | 5n | 41.2 ± 1.8 | 26.7 ± 1.5 | 62.1 ± 2.1 | 42.0 ± 4.8 | 28.8 ± 1.2 | 16.8 ± 3.4 |
| 27 | 5o | 97.7 ± 0.2 | 93.6 ± 0.3 | 99.5 ± 0.4 | 98.5 ± 0.1 | 60.8 ± 3.2 | 55.6 ± 6.5 |
| 28 | 5p | 97.7 ± 1.0 | 96.8 ± 0.0 | 97.9 ± 1.0 | 96.4 ± 0.6 | 66.3 ± 5.6 | 63.7 ± 5.2 |
| 29 | 5q | 97.7 ± 0.1 | 94.0 ± 0.3 | 97.8 ± 0.7 | 95.6 ± 0.1 | 65.4 ± 4.5 | 57.0 ± 4.6 |
| 30 | 5r | 96.4 ± 0.1 | 93.5 ± 0.1 | 99.2 ± 0.2 | 97.7 ± 0.2 | 58.4 ± 1.4 | 41.7 ± 1.3 |
| 31 | 5s | 97.8 ± 0.1 | 97.6 ± 0.1 | 97.9 ± 0.3 | 97.5 ± 0.0 | 55.0 ± 4.1 | 51.7 ± 5.3 |
| 32 | 5t | 97.9 ± 0.1 | 96.6 ± 0.1 | 99.8 ± 0.4 | 97.6 ± 0.6 | 53.3 ± 0.5 | 48.0 ± 1.9 |
| 33 | 5u | 96.0 ± 0.3 | 69.4 ± 6.5 | 99.6 ± 0.2 | 95.4 ± 0.0 | 42.7 ± 4.5 | 21.7 ± 0.7 |
| 34 | 5v | 97.5 ± 0.1 | 94.1 ± 0.5 | 98.9 ± 0.0 | 98.7 ± 0.1 | 44.2 ± 5.0 | 40.8 ± 1.6 |
| 35 | 5w | 97.5 ± 0.1 | 94.1 ± 0.5 | 98.9 ± 0.0 | 98.7 ± 0.1 | 44.2 ± 5.0 | 40.8 ± 1.6 |
|
| 73.9 ± 1.1 | 29.3 ± 1.7 | 78.8 ± 6.6 | 46.7 ± 2.3 | 39.0 ± 3.5 | 15.6 ± 4.1 | |
The average of three trials.
EC50 values of compounds 5o–5w against Xoo, Xac, and Psaa
| Compound | Regression equation | Correlation coefficient ( | EC50 (μg mL−1) |
|---|---|---|---|
|
| |||
| Bismerthiazol |
| 0.9595 | 82.3 ± 5.1 |
| 5o |
| 0.9856 | 15.0 ± 0.8 |
| 5p |
| 0.9683 | 11.7 ± 0.4 |
| 5q |
| 0.9883 | 12.6 ± 0.5 |
| 5r |
| 0.9835 | 13.4 ± 0.4 |
| 5s |
| 0.9530 | 7.6 ± 0.3 |
| 5t |
| 0.9838 | 9.1 ± 0.3 |
| 5u |
| 0.9667 | 15.9 ± 0.8 |
| 5v |
| 0.9870 | 29.5 ± 1.4 |
| 5w |
| 0.9861 | 7.9 ± 0.4 |
|
| |||
| Bismerthiazol |
| 0.9599 | 61.0 ± 4.4 |
| 5o |
| 0.9394 | 2.5 ± 0.1 |
| 5p |
| 0.9082 | 2.8 ± 0.2 |
| 5q |
| 0.9371 | 4.7 ± 0.2 |
| 5r |
| 0.9804 | 6.4 ± 0.3 |
| 5s |
| 0.9176 | 2.9 ± 0.2 |
| 5t |
| 0.9309 | 2.9 ± 0.2 |
| 5u |
| 0.9466 | 6.0 ± 0.3 |
| 5v |
| 0.9762 | 6.4 ± 0.4 |
| 5w |
| 0.9782 | 2.8 ± 0.2 |
|
| |||
| Bismerthiazol | >100 | ||
| 5o |
| 0.9104 | 44.0 ± 3.8 |
| 5p |
| 0.9581 | 26.3 ± 2.2 |
| 5q |
| 0.9199 | 36.3 ± 2.7 |
| 5r |
| 0.9779 | 56.4 ± 5.1 |
| 5s |
| 0.9784 | 62.6 ± 5.3 |
| 5t |
| 0.9650 | 47.0 ± 3.7 |
| 5u |
| 0.9821 | 55.6 ± 4.6 |
| 5v | >100 | ||
| 5w | >100 | ||
The average of three trials.